Oral amyloidosis: A case report and diagnostic algorithm

Sudip Indu¹, Indranil Deb Roy², Rohit Tewari³, Suman Pramanik⁴

¹Division of Oral Pathology, Army Dental Centre (R and R), ²Armed Forces Dental Clinic, Department of ³Pathology and ⁴Hematology, Army Hospital (R and R), New Delhi, India

INTRODUCTION

Most of the clinicians and pathologists would invariably agree to the fact that amyloidosis is a mystifying disease, often only considered following an unexpected pathology report. Essentially, amyloidosis is a complex disease characterized by tissue deposition of a protein forming an insoluble beta-pleated sheet structure which can eventually obstruct the normal functioning of any organ.[¹] Amyloidosis is known to occur more frequently in men than in women.[²]

Amyloidosis can be classified as primary, secondary and familial. The subtypes are currently named according to...
the specific protein that is deposited, using the prefix A for amyloid, followed by letters that indicate the protein (AL: primary or AA: secondary) and the distribution of amyloid deposition (localized or systemic). Amyloid light-chain amyloidosis is commonly associated with plasma cell disorders and multiple myeloma mostly affects the kidneys, liver, heart and nerves. Amyloid A or secondary systemic amyloidosis is usually associated with chronic infections or inflammatory diseases, such as osteomyelitis, tuberculosis, rheumatoid arthritis and Crohn’s disease.[3,4] Amyloidosis of the oral cavity, a form of localized disease, usually affects the tongue less commonly the gingiva. When the tongue is affected, it can result in macroglossia furthering which systemic manifestation should be evaluated.[5] We report a case of amyloidosis of the tongue that was diagnosed as one of the first manifestations of the disease, restressing on the fact that our oral cavity is the mirror of our general health.[6]

**CASE REPORT**

An 83-year-old male patient, a former smoker, presented to the outpatient department with burning sensation in the mouth for the past 3–4 months with difficulty to raise or protrude the tongue for the past 1 year. The patient described gradual deterioration of his general health over the past few months with generalized fatigue.

On extraoral examination, raised hyperpigmented violaceous plaques were noticed on both sides of the face and back. No significant hindrance to the daily routine activity of the individual because of the plaques was reported [Figure 1a and b].

On intraoral examination, a blanched white appearance of the tongue with hard and fibrous consistency was noticed. The lower labial mucosa also gave a blanched appearance. However, no palpable fibrous bands were noticed intraorally in any of the sites. There was the indentation of the teeth on the lateral border of the tongue on each side along with obvious restricted movement [Figure 2a and b]. Incisional biopsy was performed from both sides of the tongue; however, during the procedure, the surgeon hardly observed any bleeding from the biopsy/surgical site.

**Figure 1:** (a) Multiple hyperpigmented violaceous plaques on either sides of the face. (b) Hyperpigmented violaceous plaques on the back

**Figure 2:** (a): Restricted movement of the tongue. (b) Lateral Indentation of the teeth on the tongue

**Figure 3:** (a) Photomicrograph showing surface stratified squamous epithelium with submucosa showing a dense collection of amorphous material. (black arrows) (H&E, x4). (b) Photomicrograph showing amorphous material to be acellular and eosinophilic in nature. (Black arrows) (H&E, x10)

**Figure 4:** (a) Sections stained were positive for Congo red as the amorphous material was congophilic. (Black arrows) (x10). (b) Under polarizing microscopy, sections showed characteristic apple-green/orangish birefringence. (Black arrows)
Biopsy of the tongue on H and E sections showed a fragment of mucosa with surface stratified squamous epithelium and adjacent connective tissue with mild inflammatory infiltrate. The submucosa showed amorphous, acellular and eosinophilic material probably suggestive of Amyloid which was diffusely present intermixed with loosely arranged collagen fibers [Figure 3a and b].

On special stain with Congo Red, the eosinophilic material stained in a pale red orangish color confirming the presence of amyloid [Figure 4a]. Under polarizing microscopy, apple-green/yellow birefringence was noted which was diagnostic of amyloidosis [Figure 4b].

On histopathological confirmation, the patient was referred to the hematology department for systemic evaluation and further management. On primary investigation, blood picture was within normal limits. His hemoglobin was 14.4 g/dl, white blood cell: 1205 × 10⁹/l and platelet: 3.63 × 10⁹/l; peripheral blood smear was normal. His serum electrolytes, renal and liver function tests were well within normal limits. Serum electrophoresis was positive for M-band. An entire panel of investigations was advised by the hematologist, findings of which are enumerated in Table 1.

Immunohistochemistry for subtyping on PEFE- Paraffin Embedded Formalin Fixed block was carried out which showed kappa light chain restriction (3+) positivity compared to lambda (1+). SAA evaluation was negative [Figure 5a and b].

Her bone marrow biopsy showed mild plasmacytosis. Two-dimensional echocardiography showed decreased left ventricular (LV) ejection fraction (around 45%) highlighting a definite underlying cardiac disease. Correlating with all the investigation reports, a diagnosis of Light Chain Deposition Disease (k-kappa light chain) was rendered.

The patient has now been put on injection bortezomib 2 mg SC and tablet dexamethasone 10 mg both for weekly administration for an initial period of 7 weeks. He has also been supplemented with tablet doxycycline, tablet acyclovir, tablet Shelcal and tablet Vitamin D3.

After about 2 months of therapy, the results were encouraging as there has been a significant reduction in his burning sensation complaint from the oral cavity with partial relief in his restricted tongue movements. Overall, the treatment response was more than satisfactory in a limited time period of 2 months.

**DISCUSSION**

Amyloidosis is basically caused by extracellular accumulation

---

**Table 1: The entire panel of investigations, present readings and its relevance**

| Investigation                                      | Relevant findings                                           |
|---------------------------------------------------|------------------------------------------------------------|
| CBC, blood sugar profile, HbA1C                   | Increase RDW, TLC, neutrophils, 6.8 (HbA1c)               |
| Lipid profile, LFT, KFT                           | Within normal limits                                       |
| Ultrasound, serum electrolytes                    | Kidney and gall bladder show tiny echogenic foci. Rest within normal limits |
| Anti-ds DNA Ab serum                              | Within normal limits                                       |
| p-ANCA, MPO antibody serum, c-ANCA serine proteinase | Decreased IgM level                                       |
| Serum immunoglobulin profile                      | Serum ‘M’ spike seen in gamma globulin region, no M spike seen in urine |
| SPEP, 24 h urine protein electrophoresis          | 1841 pg/dl showing cardiac function getting effected      |
| NT PRO BNP                                        | Underlying cardiac disease, LVEF 45%, old MI              |
| Doppler echocardiography                          | No metabolically active lesion in tongue or rest of body   |
| Whole body PET scan                               | M spike seen as IgG, Kappa                                 |
| FISH cytogenetics                                 | Kappa free light chain increased, altered kappa/lambda ratio of 18.68 suggestive of monoclonal gammopathy with renal impairment |
| Serum immunofixation/immunotyping                 | 12% mature large pleomorphic plasma cells were seen suggestive of mild plasmacytosis |
| SFLC assay                                        |                                                            |
| Bone marrow aspiration/biopsy                     |                                                            |
Indu, et al.: Oral amyloidosis: A case report and diagnostic algorithm

Once a patient develops systemic disease, diagnostic investigations both primary and secondary that needs to avert the development of irreversible conditions such as cardiomyopathy.\[10]\n
After a tissue biopsy has been recognized, confirmation of AL disease requires bone marrow aspirate and biopsy showing predominance of normal or abnormal plasmacytosis or presence of amyloid as was seen in our present case. Serum protein electrophoresis (SPE) is used to identify patients with monoclonal gammopathies such as multiple myeloma, Waldenstrom macroglobulinemia and AL amyloidosis. SPE has good sensitivity in detecting intact monoclonal protein but has limited sensitivity in detecting monoclonal free light chains (FLCs).

Immunofixation electrophoresis (IFE) is used for immunotyping of monoclonal proteins which identifies the monoclonal immunoglobulin heavy chain (gamma, alpha and mu) and/or light chain type (kappa or lambda). IFE along with SPE is a test recommended as an initial screening panel and also for confirmation of complete response to therapy. The serum FLC assay is quantitative and its utility is not only in making the diagnosis but also in assessing progression and response to treatment.\[11,12\] Combination of FLC with SPE and IFE improves the sensitivity in diagnosing by 99%.

The patient was also evaluated for perinuclear-antineutrophil cytoplasmic antibodies (ANCA), cytoplasmic-ANCA and anti-double stranded DNA antibodies to rule out systemic vasculitis, Wegener’s granulomatosis and systemic lupus erythematosus; however, in our case, both the tests were noncontributory negating the possibility of any of the above disease process, contrary to the findings in the case reported by Liakou et al.\[13\]

Lehrke et al. conducted prognostic value evaluation of N-terminal pro-b-type natriuretic peptide (NT-pro BNP) in patients with AL and Transthyretin(TTR) amyloidosis and postulated that it can serve as a healthy correlation factor for myocardial amyloid burden such as LV-mass and Late Gadolinium enhancement (LGE), supporting the concept of NT-proBNP as a biomarker reflecting the severity of cardiac amyloid infiltration.\[14\] Our present case showed levels of 1841 pg/ML which was well above the permissible range signifying the relevance of NTProBNP as a potential novel biomarker for assessing cardiac function and status in patients affected with amyloidosis.

An initial diagnosis of AL amyloidosis can be suspected by a clinician in a patient with nephrotic range proteinuria, heart failure with preserved ejection fraction,\[15\] non-diabetic peripheral neuropathy,\[16\] unexplained hepatomegaly\[17\] or diarrhea.\[18\]

Correct classification of the type of amyloid through IHC and its biochemical nature is important for treatment consequences.\[19\] However, though expensive and less frequently available, the gold standard for subtyping of the nature of amyloid protein subunit will only be laser capture mass spectroscopic proteome analysis.\[20\]

The aim of AL amyloidosis therapy should be to swiftly decrease the amyloidogenic monoclonal light chain load, by controlling the underlying plasma cell dyscrasia, if any.\[21\]

A therapeutic strategy can also involve dissolving amyloid deposits or at least preventing their fresh accumulation. Patients with localized amyloidosis generally do not require systemic therapy, and management can be supportive or localized, chemotherapy or surgical excision.\[22\] The treatment options for systemic amyloidosis include chemotherapy with or without autologous stem cell transplant.

Clinical relevance
This case brings out the clinicopathological profile of patients with amyloidosis and the entire panel of investigations both primary and secondary that needs to
be carried out before finalizing a treatment modality in a patient [Figure 6]. Close monitoring and regular follow-up is critical for successful management of patients.\[19\]

**CONCLUSION**

Amyloidosis is difficult to be recognized early due to its varied symptoms, broad array of manifestations and rarity. Early diagnosis will guarantee early therapeutics which will ensure maximum benefit to the patient.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initial(s) will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Mollere P, Ranaut P, Gottlieb D, Goodman H. How to diagnose amyloidosis. Int Med J 2014;44:7-17.
2. Murthy P, Laing MR. Macroglossia. BMJ 1994;309:1386-7.
3. Shah KB, Inouye, Mehra MR. Amyloidosis and the heart: A comprehensive review. Arch Intern Med 2006;166:1805-13.
4. Ensign WG. Macroglossia as a manifestation of primary systemic amyloidosis; report of a case. J Am Med Assoc 1952;149:136-8.
5. Sanchorawala V. Light-chain (AL) amyloidosis: Diagnosis and treatment. Clin J Am Soc Nephrol 2006;1:1331-41.
6. Singh S, Shivhare UD, Sakarkar SN. Oral infections, a mirror of our overall health condition: An overview. Int J Pharm Life Sci 2013;4:2976-82.
7. Gillmore JD, Hawkins PN. Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol 2013;9:574-86.
8. Aono J, Yamagata K, Yoshida H. Local amyloidosis in the hard palate: A case report. Oral Maxillofac Surg 2009;13:119-22.

9. Stoopler ET, Vogl DT, Alawi F, Greenberg MS, Sollecito TP, Salazar G, et al. The presence of amyloid in abdominal and oral mucosal tissues in patients initially diagnosed with multiple myeloma: A pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:326-32.

10. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica 2014;99:209-21.

11. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119:274-8.

12. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44.

13. Liakou CI, Koh J, Tsimpidakis A, Rios K, Paskalis C, Pipilis A, et al. A Tongue Lesion as a sign of a systemic disease. Case Rep Med 2016;2016:6723575.

14. Lehrke S, Steen H, Kristen AV, Mertert C, Lossnitzer D, Dengler TJ, et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: New evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid 2009;16:187-95.

15. Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J 2018;8:44.

16. Schelbert EB, Miller CA. Cardiac amyloidosis as a potential confounder in heart failure with preserved ejection fraction trials. JACC Heart Fail 2017;5:617.

17. Mauermann ML. Paraproteinemic neuropathies. Continuum (Minneap. Minn) 2014;20:1307-22.

18. Mardinger O, Rotenberg L, Chaushu G, Taicher S. Surgical management of macroglossia due to primary amyloidosis. Int J Oral Maxillofac Surg 1999;28:129-31.

19. Matsuo FS, Barbosa de Paulo LF, Servato JP, de Faria PR, Cardoso SV, Loyola AM. Involvement of oral tissues by AL amyloidosis: A literature review and report of eight new cases. Clin Oral Investig 2016;20:1913-20.

20. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry–based proteomic analysis in clinical biopsy specimen. Blood 2009;114:24.

21. Gorevic PD. Amyloid and inflammation. Proc Natl Acad Sci U S A 2013;110:16291-2.

22. Pentenero M, Davico Bonino I, Tomasini C, Conrotto D, Gandolfo S. Localized oral amyloidosis of the palate. Amyloid 2006;13:42-6.